Literature DB >> 6817367

Partial improvement in negative schizophrenic symptoms after amphetamine.

B Angrist, E Peselow, M Rubinstein, J Corwin, J Rotrosen.   

Abstract

In stable schizophrenic outpatients with predominantly "defect state" symptomatology amphetamine caused a reduction in negative symptoms that was statistically significant but not complete (i.e. these symptoms remained clinically discernible). The possibility that dopaminergic hypofunction contributes some elements to the schizophrenic defect state is presented, along with some limited data compatible with this concept. These findings are compared to prior studies in recently hospitalized schizophrenic subjects, and discussed with respect to recent theoretical concepts regarding the role of dopamine in schizophrenic psychopathology.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6817367     DOI: 10.1007/bf00432248

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

1.  Clinical effect of L-dopa on schizophrenia.

Authors:  C Ogura; A Kishimoto; T Nakao
Journal:  Curr Ther Res Clin Exp       Date:  1976-09

2.  The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo.

Authors:  J Gerlach; K Lühdorf
Journal:  Psychopharmacologia       Date:  1975-10-14

3.  Behavioral effects of L-dopa in schizophrenic patients.

Authors:  B Angrist; G Sathananthan; S Gershon
Journal:  Psychopharmacologia       Date:  1973-07-04

4.  Central dopamine turnover in schizophrenic syndromes.

Authors:  M B Bowers
Journal:  Arch Gen Psychiatry       Date:  1974-07

5.  Provocation of schizophrenic symptoms by intravenous administration of methylphenidate.

Authors:  D S Janowsky; M K el-Yousel; J M Davis; H J Sekerke
Journal:  Arch Gen Psychiatry       Date:  1973-02

6.  Effect of L-dopa in schizophrenia.

Authors:  K Inanaga; K Inoue; H Tachibana; M Oshima; T Kotorii
Journal:  Folia Psychiatr Neurol Jpn       Date:  1972

7.  Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.

Authors:  B Angrist; J Rotrosen; S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

Review 8.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

9.  Cerebrospinal fluid amine metabolites in acute schizophrenia.

Authors:  R M Post; E Fink; W T Carpenter; F K Goodwin
Journal:  Arch Gen Psychiatry       Date:  1975-08

10.  Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine.

Authors:  C Kornetsky
Journal:  Arch Gen Psychiatry       Date:  1976-12
View more
  14 in total

Review 1.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

2.  Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography.

Authors:  A Wolkin; B Angrist; A Wolf; J Brodie; B Wolkin; J Jaeger; R Cancro; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Amphetamine and negative symptoms of schizophrenia.

Authors:  M Sanfilipo; A Wolkin; B Angrist; D P van Kammen; E Duncan; S Wieland; T B Cooper; E D Peselow; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

4.  Amphetamine response and relapse risk after depot neuroleptic discontinuation.

Authors:  B Angrist; E Peselow; M Rubinstein; A Wolkin; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 5.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

6.  The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex.

Authors:  Zhimin Li; Mona Boules; Katrina Williams; Joanna Peris; Elliott Richelson
Journal:  Brain Res       Date:  2009-11-27       Impact factor: 3.252

7.  Mood responses of remitted schizophrenics to methylphenidate infusion.

Authors:  D Robinson; D Mayerhoff; J Alvir; T Cooper; J Lieberman
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set shifting and prepulse inhibition in rats.

Authors:  Alice Egerton; Lee Reid; Sandie McGregor; Susan M Cochran; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2008-04-23       Impact factor: 4.530

9.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 10.  The early identification of psychosis: can lessons be learnt from cardiac stress testing?

Authors:  Swapnil Gupta; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2015-11-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.